New Brunswick, New Jersey, United States, January 2026 – Kate (Geier) Cummings has been appointed as Head of HR, R&D Therapeutic Areas & Oncology TA at Johnson & Johnson, where she will lead human resources strategy for critical research, therapeutic innovation and oncology programs that drive Johnson & Johnson’s global innovation pipeline.
In her immediate prior role at Johnson & Johnson, Kate (Geier) Cummings served as Head of HR, Neuroscience R&D, where she led workforce strategy, leadership development and talent frameworks supporting neuroscience research programs.
Earlier, she was Head of HR, Cardiovascular, Metabolism, Retinal, and Pulmonary Hypertension R&D at Johnson & Johnson, where she supported multi-therapeutic R&D portfolios and strengthened workforce capability planning.
She also served as Head of HR, NA Strategic Partnership Group and previously led enterprise transformation programs as HR Leader – Medical Devices Global Strategic Capabilities and HR Leader – Medical Devices Transformation, playing a key role in strengthening Johnson & Johnson’s MedTech workforce ecosystem.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company dedicated to advancing health through innovation in Innovative Medicine and MedTech. With a strong legacy of scientific excellence, the company develops smarter, more personalized healthcare solutions that improve patient outcomes and enable breakthroughs across therapeutic areas worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
